Topic: outcomes

Novo Nordisk

Novo's new GLP-1 semaglutide slashes heart risks by 26%

Novo Nordisk's blockbuster GLP-1 diabetes drug Victoza has been losing market share to new rival Trulicity and its convenient weekly dosing. But Novo could regain its edge yet: It has a weekly follow-up in the works, semaglutide, and on Friday, that drug showed it could cut cardiovascular risks by 26%.

GSK inks money-back deal on $665K gene therapy Strimvelis

GlaxoSmithKline has struck a money-back guarantee on its gene therapy Strimvelis. The once-and-done treatment for “bubble boy” disease, only the second of its kind, raised questions about pricing and payment in the up-and-coming field. GSK’s arrangement offers some potential answers.